ECM proteins are also being targeted or modulated in various therapeutic strategies to mitigate joint damage in RA like matrix metalloproteinase (MMP) inhibitors, TNF-α and IL-1 inhibitors, hyaluronan (hyaluronic acid) therapy, and collagen-based therapeutics [46,47]. Here, TNF is linked to rheumatoid arthritis.